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Dear Sir,
We agree with the interesting points made by Koutsikos et
al. They confirm the feasibility of the combined use of
bone-seeking radiopharmaceuticals and bisphosphonates
and highlight the potential benefit of this combined
treatment. We would like to stress the importance to study
multimodality treatment strategies in well-designed clinical
trials. These trials should evaluate the multidimensional
character of pain, as well as survival, and they should
incorporate imaging modalities for response stratification.
Bone-seeking radiopharmaceuticals are indicated for the
relief of bone pain in patients with multiple painful
osteoblastic metastases. Several new approaches are being
studied not only to improve treatment efficacy related to
pain response but also to extend efficacy by improving
overall survival. As a single treatment modality, treatment
at short intervals has shown to be beneficial with regard to
pain palliation and survival [1]. However, most progress
has been made with combinations of treatment modalities,
for example, bone-seeking radiopharmaceuticals and
chemotherapy [2].
In a recent publication, we showed the feasibility of
153Sm-EDTMP combined with zoledronic acid in hormone-
refractory prostate cancer patients [3]. The combination of
these two phosphate-based pharmaceuticals does not lead to
competition in uptake at the level of the calcified bone
matrix, nor does it lead to unacceptable toxicity. As a phase
I study, it was not designed to study efficacy. However, as
an illustration of potentially increased efficacy, two patients
showed a complete remission of pain and a remarkable
decline in prostate-specific antigen levels over pretreatment
values (−71% and −43%), and markers of bone metabolism
(−65% and −90%) over a period of almost 6 months. These
results suggest a clinical benefit. But, further research is
needed to explore the possible benefit of bone-seeking
radiopharmaceuticals in combination with bisphosphonates,
preferably in phase II and phase III randomized controlled
settings.
In the past, our center performed a double-blind,
placebo-controlled, randomized trial to study the efficacy
of
186Re-HEDP compared to placebo [4]. Pain relief was
assessed using an electronic diary containing questions
reflecting the multidimensional character of pain. Daily
pain assessment was mandatory because it fluctuated day
by day. Besides a visual analog scale for pain and the
assessment of daily activities, a medication index score was
also registered. This complex method of evaluation showed
a significant decrease of pain in the treated population.
Besides this, the study illustrated the difficulty of pain
response as an endpoint and the necessity of a well-
designed method for pain evaluation. Although a survival
benefit could not be detected in this study using
186Re-
HEDP as a single modality treatment, survival should
be studied in future trials focusing on the efficacy of
bone-seeking radiopharmaceuticals in combination with
bisphosphonates.
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Utrecht, The NetherlandsSeveral clinicians have postulated the multimodality
approach for the treatment of hormone-refractory prostate
cancer patients with painful osseous metastases. Combina-
tions of multiple single treatment modalities may lead to an
improvement of clinical benefit beyond an additive effect
alone. From all available single-agent modalities, docetaxel
is currently the first choice because of its proven efficacy
on patients’ survival [5]. Its toxicity is considerable, but
responders show a clear benefit with regard to quality of
life and survival. A combination of radiopharmaceuticals
and chemotherapy might be an interesting therapeutical
option. Besides the clinical benefit of each pharmaceutical
separately, the radiation-sensitizing effect of chemotherapy
may lead to synergy and a further improvement of clinical
benefit. The combined use of chemotherapy as a radio-
sensitizer is well known in the field of external beam
radiotherapy but must still be explored in the field of
radionuclide therapy. Potential radiation modifiers may be
docetaxel or other chemotherapeutics (such as platinum
compounds or 5-FU). In hormone-refractory prostate cancer
patients, continuous treatment with hormones and
bisphosphonates in combination with periodical adminis-
trations of a bone-seeking radiopharmaceutical, modified
by chemotherapy, may prove to be an effective regimen
(Fig. 1). Such a regimen benefits from (1) the effects of
repeated treatment with radiopharmaceuticals, bisphospho-
nates, and chemotherapy as single-agent modalities and (2)
the radiation-sensitizing effects of chemotherapy. Different
possible strategies should be studied in the future.
Last but not least, one of the greatest challenges in the
field of nuclear oncology and oncology in general will be
the selection of responders and nonresponders. Especially
in hormone-refractory prostate cancer, a minority of treated
patients show clinical benefit. It will prove to be beneficial
to patients, as well as cost-effective, to recognize those who
respond to the proposed treatment regimen. Molecular
imaging may play a crucial role in identifying these
subjects. In hormone-refractory prostate cancer patients,
several tracers are being developed and studied for positron
emission tomography imaging [6]. Stratification of patients
and the development of new treatment strategies will lead
to improvement of efficacy with improved overall survival.
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